Multiple vaccination including serogroup C meningococcus

Details Multiple vaccination including serogroup C meningococcus Multiple vaccination including serogroup C meningococcus

2011-08-30

2011-08-30

Navarro, Albert (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S193100, C424S197110, C424S234100, C424S236100, C530S350000

Reexamination Certificate

active

08007807

ABSTRACT:
Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellularB. pertussisantigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide fromStreptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide fromNeisseria meningitidisserogroup C.

REFERENCES:
patent: 2003/0180316 (2003-09-01), Boutriau et al.
patent: WO 02/00249 (2002-01-01), None
patent: WO 02/080965 (2002-10-01), None
patent: WO 2005/004909 (2005-01-01), None
patent: WO 2006/113528 (2006-10-01), None
patent: WO 2007/000314 (2007-01-01), None
patent: WO 2007/000332 (2007-01-01), None
Halperin, S. et al. “Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis . . . ” Clin Invest Med, 25(6): 243-251 (2002).
Slack, M. et al. “Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular . . . ” JID, 184(12): 1617-1620 (2001).
Buttery, J. et al. “Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants” JAMA, 293(14): 1751-1758 (2005).
Eskola, J. et al. “Reactogenicity and immunogenicity of combined vaccines for bacteraemic diseases caused by Haemophilus influenzae type b . . . ” VACCINE, 8(2): 107-110 (1990).
Rennels, M. et al. “Safety and immunogenicity of combined conjugate 9-valent S. pneumoniae-meningococcal group C . . . ” 41st ICAAC Abstracts, 41: 283 (2001).
Tejedor, J. et al. “Immunogenicity and reactogenicity of a three-dose primary vaccination course with a . . . ” The Pediatric Infectious Disease Journal, 23(12): 1109-1115 (2004).
Tejedor, J. et al. “Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria . . . ” The Pediatric Infectious Disease Journal, 25(8): 713-720 (2006).
Kitchin, N. et al. “Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus . . . ” Archives of Disease in Childhood, 92(1): 11-16 (2007).
Tejedor, J. et al. “Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus . . . ” The Pediatric Infectious Disease Journal, 26(1): 1-7 (2007).
Tejedor, J. et al. “Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV . . . ” The Pediatric Infectious Disease Journal, 25(10): 943-945 (2006).

Affiliated with

Also associated with

Rating

Multiple vaccination including serogroup C meningococcus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multiple vaccination including serogroup C meningococcus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple vaccination including serogroup C meningococcus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2644271